Research programme: CNS disease therapeutics - Bristol-Myers Squibb

Drug Profile

Research programme: CNS disease therapeutics - Bristol-Myers Squibb

Alternative Names: Disease activated CNS therapeutics; pH-activated CNS therapeutics

Latest Information Update: 06 Oct 2014

Price : $50

At a glance

  • Originator NeurOp
  • Developer Bristol-Myers Squibb; NeurOp
  • Class Small molecules
  • Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cerebral ischaemia; Major depressive disorder; Pain

Most Recent Events

  • 02 Oct 2014 Preclinical development is ongoing in the US
  • 14 Dec 2011 Bristol-Myers Squibb extends collaboration with NeurOp for the development of NR2B NMDA receptor antagonists for the treatment of Depression and Neuropathic pain
  • 27 Jul 2011 NeurOp receives National Institutes of Health grant from the National Institute of Neurological Disorders and Stroke for preclinical development in Ischaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top